Condition: Hidradenitis Suppurativa · Sponsor: Tulane University
This is a phase 2a, open label study. As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.
This description comes directly from the study's public registry record.
Carole Bitar, MD · 504-988-5114 · cbitar@tulane.edu
Edward Coleman, MS · 504-988-5135 · ecoleman@tulane.edu
Always discuss trial participation with your own doctor first.
| Lakeview Hospital | Covington, Louisiana, United States | Recruiting |
| Lakeside Hospital | New Orleans, Louisiana, United States | Recruiting |
| LCMC Multi-speciality Clinic | New Orleans, Louisiana, United States | Recruiting |
| University Medical Center | New Orleans, Louisiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07077902